Posted by Michael Wonder on 18 Jun 2025
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
18 June 2025 - Today, the FDA approved tafasitamab-cxix (Monjuvi, Incyte) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.
Efficacy was evaluated in inMIND, a double-blind, placebo-controlled trial randomising 548 patients with relapsed or refractory follicular lymphoma to receive tafasitamab-cxix or placebo with lenalidomide and rituximab.
